Stocks
Edgewise Therapeutics, Inc.EWTX
NASDAQHealthcareBiotechnology$37.02
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral small-molecule therapies for rare neuromuscular and cardiac disorders. Its lead candidate, edasalonexent, targets Duchenne muscular dystrophy, with additional programs in cardiac conditions. Investors track the stock for its pipeline catalysts and potential in underserved rare disease markets.
52W Range: $14.68-$48.51
Congressional Interest in Edgewise Therapeutics, Inc. (EWTX)
No congressional trades have been disclosed for Edgewise Therapeutics, Inc. (EWTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading EWTX?
No congressional trades found for this stock.